CCO Independent Conference Coverage

2004 Annual Meeting of The American Association for the Study of Liver Diseases*

October 29-November 2, 2004 | Boston, Massachusetts

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Treatment of HBV

Track 1 of 5

Program Director:
Patrick J. Lynch, MD

Faculty:
	Geoffrey M. Dusheiko, MD, FCP(SA), FRCP Emmet B. Keeffe, MD, MACP Marion G. Peters, MD

Treatment of HCV

Track 2 of 5

Program Director:
Patrick J. Lynch, MD

Faculty:
	Gary L. Davis, MD Adrian M. Di Bisceglie, MD, FACP Karen L. Lindsay, MD

Epidemiology and Prevention

Track 3 of 5

Capsule Summaries

Expert Analysis

Program Director:
Patrick J. Lynch, MD

Faculty:
	Beth P. Bell, MD W. Ray Kim, MD David L. Thomas, MD, MPH

Side Effects and Treatment of HIV Coinfection

Track 4 of 5

Capsule Summaries

Expert Analysis

Program Director:
Patrick J. Lynch, MD

Faculty:
	Nezam H. Afdhal, MD, FRCPI Raymond T. Chung, MD Mark S. Sulkowski, MD

Diagnostics and New Drugs

Track 5 of 5

Capsule Summaries

Expert Analysis

Program Director:
Patrick J. Lynch, MD

Faculty:
	Geoffrey M. Dusheiko, MD, FCP(SA), FRCP Robert G. Gish, MD Jean-Michel Pawlotsky, MD, PhD

CCO Daily News (Not required for CME credit)

November 3, 2004

Peginterferon has greater impact on quality of life and leads to more depression during treatment of chronic hepatitis C vs chronic hepatitis

November 2, 2004

Viremia, cirrhosis, and possibly knowledge of infection are associated with fatigue in HCV-infected VA patients

November 1, 2004

November 2, 2004

Fourteen-week course of peginterferon plus ribavirin effective for HCV genotype 2/3 patients with early virologic response

November 3, 2004

24 weeks of peginterferon alfa-2a plus ribavirin as effective as 48 weeks with higher-dose ribavirin for HCV genotype 2 and 3

November 1, 2004

November 2, 2004

Sexual transmission of HCV may be more common than previously thought

November 3, 2004

Maternal lamivudine plus perinatal HBIg and vaccine further reduces mother-to-child HBV transmission

October 31, 2004

November 1, 2004

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.